Kintara Therapeutics Invites Stockholders to Participate in Merger
Kintara Therapeutics, Inc. (NASDAQ: KTRA), an innovative biopharmaceutical company, is actively engaging its stockholders in a crucial decision regarding a proposed merger with TuHURA Biosciences, Inc. This merger aims to strengthen their oncology pipeline by leveraging combined expertise and resources. Stockholders are encouraged to take part in the upcoming Special Meeting of Stockholders to ensure their opinions are represented.
Special Meeting Details
The Special Meeting will be held virtually, making it easy for stockholders to join from anywhere. To ensure their votes count, stockholders must cast their votes by 11:59 p.m. Eastern Time on the specified date. This meeting is essential for approving the merger with TuHURA, a company recognized for its groundbreaking cancer treatments.
How to Register and Participate
Stockholders who wish to attend the Special Meeting need to register in advance. This can be done through a dedicated online portal. It’s important for interested stockholders to register early to guarantee their participation in the voting process.
Significance of the Merger
The merger with TuHURA is expected to transform both companies. Kintara's current shareholders will own a minority share of the new entity, while TuHURA shareholders will hold the majority after the merger. This collaboration aims to drive innovations and advancements in cancer therapy, particularly in addressing treatment resistance challenges.
Easy Voting Procedures
Kintara has established straightforward methods for stockholders to cast their votes. They can choose to vote by phone or online, simplifying the process for all participants.
Voting by Phone
For those who prefer to vote by phone, Kintara has partnered with Alliance Advisors for assistance. Stockholders in specific regions can call toll-free, while international participants can use local numbers for convenience.
Voting Online
Voting online is another quick and easy option. Stockholders can visit a designated website to submit their votes using their unique control number. Brokers or financial institutions will provide detailed instructions to help facilitate this process.
About TuHURA Biosciences, Inc.
TuHURA Biosciences is leading the way in immuno-oncology, developing advanced therapies that enable the body to effectively combat cancer. Their flagship product, IFx-2.0, addresses immunotherapy resistance and aims to improve treatment outcomes for patients. A Phase 3 clinical trial is on the horizon to evaluate its effectiveness in conjunction with existing therapies.
About Kintara Therapeutics, Inc.
Kintara Therapeutics is focused on transforming cancer treatments through innovative solutions. With a commitment to addressing unmet medical needs, Kintara is advancing its REM-001 therapy for a specific type of breast cancer. Their technology utilizes unique mechanisms to provide patient-centered care, showcasing impressive clinical results.
Investor Contact Information
Kintara is dedicated to maintaining transparency and open communication with its investors. Stockholders seeking more information about the upcoming merger and its implications are encouraged to reach out to Kintara’s investor relations team.
Frequently Asked Questions
What is the purpose of the Special Meeting?
The Special Meeting is designed to allow stockholders to vote on the proposed merger with TuHURA Biosciences, which is vital for enhancing collaboration in cancer therapy.
How can stockholders vote?
Stockholders can cast their votes either by phone or online using their control number. Detailed instructions will be provided by their financial intermediaries.
What will happen after the merger?
Once the merger is successfully completed, the combined entity is expected to operate under the name TuHURA Biosciences, focusing on pioneering cancer treatments.
When is the voting deadline?
Stockholders must submit their votes by 11:59 p.m. Eastern Time on the specified date before the meeting.
Who is Kintara Therapeutics?
Kintara Therapeutics is a biopharmaceutical company committed to developing innovative therapies for unmet medical needs in cancer treatment, primarily targeting specific cancer types.
